In late 2023, the FDA approved Casgevy, the first CRISPR-based medicine ever to reach patients. Within a few months, the pharmaceutical world was also consumed by another story: semaglutide and tirzepatide — incretin peptides — were rewriting the economics of metabolic medicine. Two modalities, two breakout moments, two entirely different chapters of the drug-discovery textbook. Or so it seemed.
Look closer and the line between them is dissolving. The same venture funds back both. The same delivery chemistry — lipid nanoparticles developed for mRNA vaccines — now carries base editors into the liver and peptide-nucleotide conjugates into fat cells. Verve Therapeutics and Novo Nordisk publish in adjacent issues of Nature Medicine. Academic labs use cell-penetrating peptides to shuttle Cas9 into cells that resist viral vectors. And biotech companies are increasingly forced to answer the same question from investors: given a disease, which modality wins?
This article maps that convergence. It argues that peptides and CRISPR are not rivals, but complementary layers in an emerging therapeutic stack — sometimes competing for the same indication, sometimes physically riding the same nanoparticle, and almost always solving versions of the same problem.
Two Fields, One Decade
For most of the 2010s, peptide therapeutics and gene editing developed on separate tracks. Peptides were the domain of endocrinology and metabolic disease: GLP-1 analogs, insulins, octreotide, teriparatide. Gene editing lived in academic labs and rare-disease biotechs chasing sickle cell, beta-thalassemia, and inherited blindness. The economic logic was different, the regulatory playbook was different, and the investor base barely overlapped.
Three events collapsed the distance:
- The mRNA-LNP platform matured. COVID-19 vaccines proved that lipid nanoparticles could reliably deliver nucleic acids to human cells at scale. That same chassis now carries base editors (Verve), prime editors (Prime Medicine), and peptide-nucleotide conjugates.
- Casgevy crossed the regulatory finish line. Vertex and CRISPR Therapeutics' sickle cell therapy showed that permanent genetic edits could pass FDA review. A durable edit became a real product, not a thought experiment.
- GLP-1 drugs rewrote expectations for metabolic disease. Semaglutide and tirzepatide proved patients would inject weekly — indefinitely — for a drug that worked. That created a specific tension: if chronic peptide therapy can capture this much value, what happens when a single gene edit could deliver the same benefit?
The answer, increasingly, is that the two modalities are being developed in parallel inside the same companies, for the same targets, with overlapping infrastructure.
Four Intersection Points
The convergence isn't happening in one place — it's happening at four distinct points along the therapeutic stack.
Intersection 1: Cell-Penetrating Peptides as CRISPR Delivery
The oldest and most literal intersection. Cell-penetrating peptides (CPPs) — short cationic or amphipathic sequences like TAT, penetratin, and the MPG family — have been studied since the 1990s as carriers for macromolecules that can't cross cell membranes on their own. Cas9 ribonucleoprotein complexes are exactly that kind of cargo: too big, too charged, too fragile.
Ramakrishna et al. (2014) in Genome Research first showed that conjugating Cas9 to a CPP enabled delivery and editing in human cells without any viral vector or transfection reagent. Since then, labs at Salk, the Broad, and MIT have refined the approach with engineered CPPs that improve endosomal escape and target specific tissues. For ex vivo cell therapy — where the cells are outside the body and only need a short burst of editing activity — CPP-Cas9 is now a credible alternative to electroporation, which damages cells.
The advantage is clean: no viral DNA integration risk, no mRNA immunogenicity, transient editor exposure that reduces off-target effects. The disadvantage is equally clean: CPPs are still poor at crossing the liver sinusoid, the blood-brain barrier, or most solid tumor stroma. For systemic in vivo use, LNPs currently dominate.
Intersection 2: Gene-Edited Cells That Make Peptides in Vivo
The second intersection inverts the relationship. Instead of using peptides to deliver CRISPR, you use CRISPR to engineer cells that produce therapeutic peptides inside the patient — essentially turning the body into its own injectable.
The clearest example is in hemophilia research, where AAV-delivered gene therapy produces clotting factor peptides continuously. Emerging programs extend the logic: edit hepatocytes or muscle cells to secrete GLP-1 analogs, PTH fragments for bone disease, or follistatin for muscle wasting. A 2024 report from Rejuvenate Bio described engineered hepatocytes producing follistatin in aged mice with improvements in strength and metabolic markers.
The commercial logic is compelling — a single intervention replaces a lifetime of injections — but the safety logic is terrifying. Peptide dose can't be titrated down if the edit is permanent. Every program working this intersection is now wrestling with the same question: how do you build a kill switch or reversibility into a durable edit?
Intersection 3: Peptide Drugs vs. Gene Editors for the Same Target
This is the intersection that venture boards actually fight over. For many high-value targets, a peptide drug and a gene-editing program are being developed in parallel, sometimes within a few miles of each other in Kendall Square.
PCSK9 is the textbook case. The gene was identified as a driver of familial hypercholesterolemia in 2003. Amgen's evolocumab (Repatha) — a monoclonal antibody against PCSK9 — reached the market in 2015. Novartis/Alnylam's inclisiran (Leqvio) — an siRNA — followed in 2020. Verve Therapeutics' VERVE-102 — a base editor that permanently knocks down PCSK9 in the liver — reported initial human data in 2024. Each platform hits the same protein, with progressively longer durability and progressively higher upfront risk.
Obesity is the next contested target. GLP-1 peptides dominate today. But candidate gene-editing programs targeting GIPR, INHBE, and MC4R signaling are advancing in preclinical development.
Intersection 4: Peptide-Delivered Yamanaka Factors
The fourth intersection is the most speculative and arguably the most interesting. Yamanaka factors — OCT4, SOX2, KLF4, c-MYC — reset the epigenome and, in partial-reprogramming doses, appear to reverse aspects of cellular aging (Lu et al., 2020). Almost every program to date has delivered them as DNA, mRNA, or viral vectors. That carries real risk: permanent genomic integration, tumor formation, unpredictable dosing.
Zhou et al. (2009) showed that Yamanaka factors could be delivered as recombinant proteins fused to CPPs, achieving reprogramming without any nucleic acid entering the cell. The approach was inefficient but it demonstrated principle. A handful of startups — quietly, so far — are revisiting protein and peptide delivery of reprogramming factors precisely because transient, dose-controllable exposure is safer than genetic delivery for a procedure you might one day want to repeat every few years.
Why Delivery Is the Shared Bottleneck
Strip away the modality labels and both fields spend most of their R&D budgets on the same problem: getting a large, charged, unstable molecule into the right cell type, at the right dose, without triggering immunity or off-target effects.
| Delivery vehicle | CRISPR use | Peptide use | Shared challenges |
|---|---|---|---|
| Lipid nanoparticles (LNPs) | Base editors, prime editors, mRNA-Cas9 | Peptide-siRNA conjugates, long-acting formulations | Liver tropism, immunogenicity, storage |
| Adeno-associated virus (AAV) | Durable expression of Cas9, donor templates | Engineered secretion of therapeutic peptides | Immunogenicity, cargo size, redosing |
| Cell-penetrating peptides (CPPs) | RNP delivery, ex vivo editing | Intracellular peptide therapeutics | Specificity, endosomal escape |
| Exosomes / EVs | Emerging Cas9 delivery | Natural peptide cargo carriers | Manufacturing, targeting |
| GalNAc conjugates | Liver-targeted siRNA/ASO | Liver-targeted peptide conjugates | Limited to hepatocytes |
The bottleneck isn't the editor or the peptide — it's the address label. This is why delivery-focused companies (Acuitas, Generation Bio, Prime Medicine, Capstan) matter disproportionately. Whichever company solves targeted extrahepatic delivery will shape the next decade of both fields.
Case Study: PCSK9 as a Platform Progression
No target illustrates the convergence more clearly than PCSK9. The gene encodes a protein that drags LDL receptors into lysosomes for degradation. Knock it down and LDL-C falls. Every therapeutic modality invented in the last 25 years has eventually been pointed at it.
| Era | Platform | Example | Dosing | LDL-C reduction | Durability |
|---|---|---|---|---|---|
| 1987 | Small molecule | Statins (lovastatin → rosuvastatin) | Daily oral | ~40–55% | While taken |
| 2015 | Monoclonal antibody | Evolocumab, alirocumab | Every 2–4 weeks SC | ~55–60% | Weeks |
| 2020 | siRNA (GalNAc) | Inclisiran | Every 6 months SC | ~50% | Months |
| 2024 | Base editor (LNP) | VERVE-102 | Single IV infusion | 53–69% (Ph 1b, Verve 2024) | Potentially permanent |
| Future | Engineered secreting cell / peptide | Pre-clinical | Varies | TBD | Varies |
The progression is unmistakable: each platform reduces dosing frequency in exchange for higher upfront commitment. The small molecule is cheap and reversible but requires daily adherence. The antibody is durable for weeks. The siRNA compresses dosing to twice a year. The base editor aims for a single lifetime intervention. Each step trades flexibility for durability.
PCSK9 also illustrates the "graduation" pattern: the first successful target on any new platform tends to be one where every prior modality has already proven efficacy and safety. VERVE-102's path was possible precisely because three generations of PCSK9 drugs had already mapped the risk landscape.
Case Study: Obesity and the GLP-1 Endgame
Obesity is PCSK9 ten years earlier, and with far more money on the table. Semaglutide (Wegovy) and tirzepatide (Zepbound) have transformed the field and are projected to generate $150B+ in annual revenue by the late 2020s. But both remain weekly injections, priced at roughly $1,000/month in the US, with a substantial fraction of patients discontinuing within a year.
The obvious question: could a one-time intervention capture durable metabolic benefit without lifelong injection? Several candidate genes make this more than a thought experiment. INHBE, encoding inhibin βE, was identified in a 2022 Akbari et al. paper in Nature as a loss-of-function variant associated with favorable fat distribution and lower type 2 diabetes risk in hundreds of thousands of UK Biobank participants. GPR75 variants show similar protective effects (Akbari et al., 2021, Science). And MC4R agonism is already the mechanism of the approved peptide drug setmelanotide.
Novo Nordisk, Eli Lilly, Regeneron, and Verve are all known to be watching these targets. A parallel future is plausible: peptide GLP-1/GIP agonists dominate acute weight loss for the next decade, while gene-editing programs quietly build toward durable metabolic interventions. For a deeper look at the base-editing side of that bet, see our companion analysis of whether base editing can replace GLP-1 injections.
Companies Working the Intersection
No single company owns the convergence, but a handful are visibly building across both modalities — either directly, through subsidiaries, or through deep partnerships. The table below snapshots the dual-track programs most likely to reach the clinic by the late 2020s.
| Company | Peptide / protein program | Gene-editing or nucleic acid program | Convergence angle |
|---|---|---|---|
| Novo Nordisk | Semaglutide, CagriSema, amycretin | Partnered discovery; LNP investments | Owns the metabolic peptide franchise; watching durable alternatives |
| Eli Lilly | Tirzepatide, retatrutide, orforglipron | Prime Medicine partnership, siRNA deals | Dual-tracking obesity targets |
| Verve Therapeutics | — | VERVE-102 (PCSK9), VERVE-201 (ANGPTL3) | Pure-play base editor taking on metabolic targets |
| Intellia Therapeutics | — | NTLA-2001 (TTR), NTLA-2002 (HAE) | In vivo CRISPR with LNP delivery |
| CRISPR Therapeutics | — | Casgevy, CAR-T, in vivo cardiovascular | Broad platform, expanding into metabolic |
| Amgen | Evolocumab, AMG 133 (obesity peptide) | siRNA and RNA programs | Peptide and nucleic-acid under one roof |
| Regeneron | Alirocumab, trevogrumab | Discovery via Regeneron Genetics Center | Uses human genetics to pick targets for any modality |
| Alnylam | — | Inclisiran, patisiran, vutrisiran | siRNA platform that paved the delivery road |
The pattern is clear: metabolic-disease incumbents are quietly hedging into durable modalities, while pure-play editing companies are moving into metabolic and cardiovascular indications previously owned by peptide makers. Ten years from now, the distinction between "peptide company" and "gene-editing company" may not be meaningful for these firms.
The Next Decade: What Each Platform Learns from the Other
The convergence isn't just commercial. Each platform is absorbing technical lessons from the other.
What gene editing learns from peptides:
- Target validation through reversible pharmacology. Peptide drugs prove, reversibly and dose-dependently, whether modulating a target is therapeutic. That de-risks the decision to pursue a permanent edit. No serious base-editor program goes after a target where pharmacology hasn't already worked.
- Manufacturing discipline. Peptide drug makers have decades of experience with cold chain, fill-finish, and regulatory expectations for parenteral biologics. Gene-editing programs are inheriting that playbook.
- Patient adherence data. GLP-1s have exposed how poorly lifelong injections perform in the real world — roughly 30–50% discontinuation within a year in some datasets. That failure mode is the single strongest argument for durable interventions.
What peptides learn from gene editing:
- Genomic target discovery. Human-genetics-first programs (Regeneron, Alnylam, Verve) identify loss-of-function variants that are protective. Those genes become targets for any modality — including peptide agonists or antagonists of their gene products.
- Delivery innovation. LNP chemistry developed for base editors is improving oral peptide absorption and tissue targeting. Peptide-nucleotide conjugates inherit GalNAc and antibody-drug-conjugate strategies.
- Durability expectations. Monthly, quarterly, and semiannual dosing regimens for peptides are being reimagined because siRNA and antibody drugs have shown patients will accept them.
Key Takeaways
- Peptides and gene editing are converging on the same targets, delivery systems, and patient populations — they are no longer separate fields.
- Four distinct intersection points matter: CPP-based CRISPR delivery, gene-edited cells producing peptides, parallel peptide vs. editor programs, and peptide-delivered reprogramming factors.
- Delivery is the shared bottleneck. LNPs, AAVs, CPPs, and exosomes all solve versions of the same "get this into that cell" problem.
- PCSK9 is the textbook of platform progression: small molecule → antibody → siRNA → base editor. Each step trades dosing flexibility for durability.
- Obesity is the next contested target, with peptides dominating today and candidate gene-edit programs quietly advancing.
- Companies like Novo, Lilly, Amgen, Regeneron, and Verve are building dual-track programs across both modalities.
- No modality wins universally. The next decade will be defined by the stack, not a single winner.
Frequently Asked Questions
Are peptides and CRISPR drugs competing or complementary?
Both, depending on the indication and the patient. For acute, reversible conditions or situations where titration matters, peptides have strong advantages. For high-value chronic targets where lifelong dosing is impractical, gene editing offers durability. In many programs the two are being developed in parallel so that patients and payers eventually choose.
Can CRISPR be delivered with peptides alone, without viral vectors or LNPs?
Yes, for ex vivo applications and some in vivo tissues. Cell-penetrating peptides fused to Cas9 ribonucleoproteins can enter cells and edit genes (Ramakrishna et al., 2014). For systemic delivery to organs like the liver, LNPs currently outperform peptide-only delivery.
Why is PCSK9 the most studied target in this convergence?
Because every successful PCSK9 drug has validated the same protein. Statins set the precedent, evolocumab proved direct PCSK9 inhibition was safe and effective, inclisiran proved durable knockdown was tolerable, and Verve's VERVE-102 is testing whether permanent knockdown is viable. Each program de-risked the next.
Could a single gene edit ever replace GLP-1 injections?
It's plausible but not yet proven. Candidate targets like INHBE, GPR75, and GIPR have human genetic validation. A durable edit in one of these would in principle deliver metabolic benefit without weekly injection, but safety, reversibility, and regulatory concerns are significant.
What are the biggest risks in peptide-delivered gene editing?
Inefficiency compared to LNPs and AAVs, limited tissue reach, manufacturing complexity, and immunogenicity of certain CPP sequences. Advantages include transient exposure, no genomic integration, and simpler ex vivo workflows.
Will patients ever choose between a peptide and a gene-editing drug for the same condition?
Yes, and this decision is already emerging for cardiovascular disease. A patient with familial hypercholesterolemia can already choose between statins, evolocumab, and inclisiran. Once VERVE-102 or a similar base editor reaches the market, a one-time IV infusion will join that menu. Obesity is the next frontier.
Further Learning
- What Are Peptides? A Complete Guide — foundational primer on peptide biology and therapeutic classes.
- Cell-Penetrating Peptides for CRISPR Delivery — the mechanics of using peptides to shuttle gene editors into cells.
- How GLP-1 Drugs Work: Ozempic Explained — the peptide side of the obesity story.
- What is CRISPR? A Complete Guide — the canonical explainer on the gene-editing side.
- Casgevy: The Sickle Cell Milestone — the first CRISPR medicine to reach the market.
